Aix-en-provence, France

Time filter

Source Type

Attendees in Boston will see demonstrations of Aixplorer with real-time ShearWave Elastography™ and several clinical research abstracts on its use for liver stiffness measurement AIX-EN-PROVENCE, FRANCE--(Marketwired - Nov 10, 2016) - SuperSonic Imagine ( : SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will feature Aixplorer with real-time ShearWave Elastography (SWE™) at The Liver Meeting 2016 November 11 - 15 in Boston. The Company will be exhibiting in conjunction with Sandhill Scientific, Inc., their exclusive distributor in the United States for providing the Aixplorer® ultrasound system to Gastroenterologists and Hepatologists. Attendees of this meeting, held by the American Association for the Study of Liver Diseases (AASLD), will have the opportunity to learn more about SWE's value to patients with chronic liver disease. Real-time ShearWave Elastography (SWE), available only on the Aixplorer ultrasound system, is a 60-second non-invasive exam that can be used for imaging patients with chronic liver disease. SWE offers the advantage of a real-time image of liver anatomy, while also providing a color coded map and quantitative measurement of liver stiffness, making it an important parameter to enhance liver diagnostics. About 100 international publications have demonstrated the reliability and effectiveness of SuperSonic Imagine's SWE in this area. In addition, eight abstracts accepted by AASLD reporting results from clinical research studies using SuperSonic's imagine's technology will be presented as posters during the meeting: Diagnostic accuracy of Shear Wave Elastography for the assessment of liver stiffness in pediatric patients with fatty liver disease (Abstract #546) Matteo Garcovich et al. #654 Role of shear wave elastography in patients on high dose methotrexate: A prospective study (Abstract 654) Robert S. Rahimi et al. Regression of Liver Fibrosis assessed by non-invasive methods in Patients with Chronic Hepatitis C who Achieved Sustained Virologic Response after DAAs Treatment (Abstract 824) Yana Davidov et al. Prospective Comparison between Transient Elastography, Supersonic Shear Imaging, and ARFI Imaging for Predicting Fibrosis in Subjects with NAFLD (Abstract 1058) Won Kim et al. Improvement in Non-Invasive Hepatic Parameters of Nonalcoholic Fatty Liver Disease in Obese Uncontrolled Type 2 Diabetes Mellitus Patients who underwent Endoscopic Duodenal-Jejunal Bypass Liner (Endobarrier) Implantation (Abstract 1105) Oranit Cohen-Ezra et al. Probiotics do not improve hepatic outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized clinical trial (Abstract 1123) Shiri Sherf Dagan et al. 2-dimensional shear wave elastography rather than HVPG significantly improves MELD-Na to predict survival in decompensated cirrhosis patients (Abstract 1406) Maja Thiele et al. "SuperSonic Imagine's dedication to advancing the evaluation of chronic liver disease has enabled us to develop innovative solutions such as image-guided ShearWave Elastography, an accurate, easy-to-use and pain-free liver exam," explained SuperSonic Imagine Founder and Chief Innovation Officer Jacques Souquet. "We are excited to share this technology's capabilities at The Liver Meeting, where we know hepatologists from around the world will share our enthusiasm for the non-invasive quantification of liver stiffness." SSI will be exhibiting at booth #313 throughout The Liver Meeting. The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases. Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S* - Planewave UltraSensitive™ Imaging. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-29-2016 | Award Amount: 3.82M | Year: 2016

SOLUS is a trans-disciplinary 48-month project bringing together 9 partners: industries (4), academic and clinical institutions from 5 countries (engineers, physicists and radiologists) representing cutting-edge expertise in their fields, to develop an innovative non-invasive, point-of-care, low-cost, easy-to-operate, multi-modal imaging system (diffuse optics and ultrasounds/shear wave elastography) for high-specificity diagnosis of breast cancer, the most common female cancer in Europe. Mammographic screening is effective in reducing mortality, however the 10-year cumulative false-positive risk is 50-60%, leading to needless additional invasive procedures (e.g. biopsy). The project addresses the unmet clinical need for higher specificity in breast cancer imaging following screening by fully combining photonics with non-photonics techniques, developing and clinically validating innovative and previously unthinkable photonics concepts and components: time-domain small source-detector distance optical tomography, miniaturized picosecond pulsed laser sources, high-dynamic-range time-gated single-photons detectors to achieve unprecedented sensitivity and depth penetration. For the first time, this allows a comprehensive quantitative characterization of breast tissue including composition (water, lipids, collagen), functional blood parameters, morphologic information and mechanical parameters (stiffness). This innovative multi-parametric characterization will significantly improve the specificity of breast screening, with great impact on the quality of life of millions of European women every year, and huge savings for the healthcare systems. The strong involvement of leading industrial players at all levels in the value chain will push the European innovation process and make a significant contribution to ensuring Europes industrial leadership in the biophotonics healthcare market, while addressing one of the largest societal challenges in health and well-being.


AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News: SuperSonic Imagine (Euronext : SSI, FR0010526814, éligible PEA-PME) (Paris:SSI), société spécialisée dans l’échographie innovante annonce aujourd’hui l’obtention de l’autorisation réglementaire 510(k) de la Food & Drug Administration (FDA) pour la commercialisation de plusieurs innovations cliniques et de nouvelles sondes aux États-Unis. Cette autorisation inclut plusieurs nouveaux modes d’imageries récemment développés par SuperSon


AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News: SuperSonic Imagine (Euronext: SSI, FR0010526814) (Paris:SSI), a company specializing in ultrasound medical imaging, today announced that it has received 510(k) clearance from the Food & Drug Administration (FDA) for additional probes and significant clinical innovations on the Aixplorer® platform. This authorization includes numerous new imaging modes recently developed by SuperSonic Imagine: Angio PL.U.S. - PlaneWave UltraSensitive


AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News: SuperSonic Imagine (Paris:SSI) (Euronext : SSI, FR0010526814, éligible PEA-PME), société spécialisée dans l’imagerie médicale par ultrasons (échographie), annonce aujourd'hui la nomination de Mickael Brock, jusqu’alors Vice-Président du Conseil de Surveillance, en qualité de Président du Conseil de Surveillance. Mickael Brock succèdera à Hermann Requardt, qui a quitté ses fonctions pour d’autres engaments, l’empêchant de pouvoir assurer


AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News: SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814), a company specializing in ultrasound medical imaging, today announced the installation of its flagship Aixplorer ultrasound system at Knoxville Comprehensive Breast Center in Tennessee. The Aixplorer system provides premium breast imaging and unique innovations including real-time ShearWave™ Elastography (SWETM). SWE is a quick, non-invasive exam that gives practitioners a co


News Article | November 24, 2016
Site: www.businesswire.com

AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News: SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814, PEA-PME eligible), the highly-innovative ultrasound company, today announces the appointment of Michèle Lesieur as President and CEO, thus replacing Bernard Doorenbos. Michael Brock, Chairman of the Supervisory Board, says: “SuperSonic Imagine’s Supervisory Board is enthusiastic about Michèle Lesieur becoming the Company’s President and CEO. Her expertise, her leadership and h


AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News: SuperSonic Imagine (Paris:SSI): Place de cotation:   Euronext Paris Compartiment: Compartiment C Code ISIN: FR0010526814 Site web : www.supersonicimagine.fr Date   Nombre de titres composant lecapital en circulation   Nombre total de droits de vote     Total brut (1)   Total net (2) 30 octobre 2016   16 271 481   16 271 481   16 217 477 (1) Le nombre de droits de vote bruts (ou droits de vote “théoriques”) sert de base de calcul pour le


News Article | December 13, 2016
Site: www.marketwired.com

The innovative ultrasound company demonstrates to customers and investors its commitment to responsible environmental management AIX-EN-PROVENCE, FRANCE--(Marketwired - Dec 13, 2016) - SuperSonic Imagine ( : SSI) (FR0010526814), a company specializing in innovative ultrasound medical imaging, today announced that it has been certified ISO 14001 compliant by LNE certification body. This accredited third-party certification confirms that SSI has voluntarily implemented an environmental management system that benefits its customers and investors. Demonstrating a strong commitment to minimize environmental impact, SuperSonic Imagine has established a mission to design and manage our products in an eco-friendly manner, and its employees are committed to achieving this goal. "This is an important step forward for SuperSonic Imagine, where we have worked diligently to develop an environmental management system that reflects and supports the quality of our products. Our processes are now compliant with the most recent environmental management standard and all its obligations for the design, development, production, distribution, installation and servicing of diagnostic ultrasound systems," explains Laurence Hermitte, Quality & Regulatory Director at SuperSonic Imagine. "As SuperSonic Imagine continues to develop innovative technologies and grows its market leadership in ultrasound technology, our customers can be confident that we do so while adhering to ISO 14001 and all industry standards to measure and manage our environmental impact." According to the International Organization for Standardization (ISO), based in Geneva, Switzerland, "ISO 14001 is an internationally agreed standard that sets out the requirements for an environmental management system. It helps organizations improve their environmental performance through more efficient use of resources and reduction of waste, gaining a competitive advantage and the trust of stakeholders." Certified entities must demonstrate continuous improvement in their systems and their approach to environmental impacts, a commitment SSI is pleased to accept. About SuperSonic Imagine Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S - Planewave UltraSensitive™ Imaging. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.


SuperSonic Imagine hosts a symposium where key opinion leaders will discuss how UltraFast™ imaging innovations are improving their diagnostic efficiency and patient management AIX-EN-PROVENCE, FRANCE--(Marketwired - Feb 28, 2017) - SuperSonic Imagine ( : SSI) (FR0010526814), a company specializing in ultrasound medical imaging, today announced that it will feature Aixplorer®'s latest advances at the European Congress of Radiology (ECR) March 1 - 5, in Vienna, Austria. The upgrade to Aixplorer is the only UltraFast™ ultrasound system, with enhanced performance, improved workflow and diagnostic efficiency, while providing both impeccable image quality and unprecedented ultrasound innovations. SuperSonic Imagine will demonstrate live on the show floor its new innovative modes (booth #3 in Hall X5). "Meeting with colleagues from across Europe, we are excited to share the Aixplorer's new capabilities, especially the exclusive TriVu real-time simultaneous mode, which combines anatomical and functional imaging in one single acquisition," said Jacques Souquet, Founder and Chief Innovation Officer of SuperSonic Imagine. "We are also proud to show our new fusion and navigation mode. We received very positive feedback from the first users who specially appreciated its intuitive and simplistic user-interface as well as the exclusive innovative modes also available while in fusion imaging mode." Aixplorer's latest version demonstrates advancements in several respects. The new comprehensive breast package is a combination of new probes designed especially for breast imaging, resulting in a significantly improved B-mode image quality. Three essential innovations aid visualization: SWE to improve diagnostic specificity, 3D Ultrasound for improved visualization of tissue stiffness, and the unique TriVu mode combining breast anatomy, flow information and tissue stiffness in a single acquisition. Planned demonstrations include Aixplorer's new Fusion, Navigation & Needle Guidance technology, which enable users to fuse real-time ultrasound images with magnetic resonance imaging, computed tomography, positron emission tomography and 3D ultrasound, as well as with other exclusive Aixplorer modes such as SWE, Angio PL.U.S. or TriVu. This combined visualization is designed to leverage the simultaneous real-time benefits of multiple modalities for exams in complex cases, as well as for interventional imaging such as biopsy guidance or for therapy such as RF ablation. SuperSonic Imagine will also host a clinical symposium (March 1st, 12:30 - 13:30pm, Room N), "UltraFast Imaging: Innovations in ultrasound for daily practice". Prof. F.K.W. Schäfer, Dr. M. Garcovich, Dr. L. Masci and Prof. J.M. Correas will present how the use of innovative ultrasound in their daily practice help them to better assess and monitor chronic liver disease and breast and prostate cancers, as well as sports medicine conditions. The event will be LiveTweet, to follow it #SympoUltraFast. Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler, Angio PL.U.S - Planewave UltraSensitive™ Imaging and more recently TriVu. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.

Loading SuperSonic Imagine collaborators
Loading SuperSonic Imagine collaborators